Forte Biosciences, Inc. (FBRX) Q1 2021 Earnings Call

Investor webinar replay

Replay transcript excerpt

quarter 2021 conference call. My name is David and I will be the operator for this call. On the call are Paul Wagner, Chairman and Chief Executive Officer of Forte Biosciences, Dan Burge, Forte's Chief Medical Officer, and Tony Riley, Forte's Chief Financial Officer. Before I turn the call over to Paul and Tony to discuss the business and financial highlights of the first quarter, I would like to make a comment regarding forward-looking statements. Many of the statements made during the call today are forward-looking statements. including statements with respect to the company's cash position and the potential development timeline of the company's product candidate. Actual results could differ materially from those contemplated by our forward-looking statements, and reported results should not be considered as an indication of future performance. Please look at our filings with the SEC for a discussion of the factors that could cause our results to differ materially. Additional information is also set forth in Forte's quarterly report on Form 10-Q for the quarter ended March 31, 2021, as filed today with the SEC, and in Forte's annual report on Form 10-K for the year ended December 31, 2020, as filed with the SEC on March 16, 2021. The forward-looking statements on this call are based on information available to us, and we disclaim any obligation to update these forward-looking statements except as required by law. I will now turn this over to Tony, who will discuss the financial highlights of the first quarter of 2021. Thank you. I will now give an update of our financial results for the first quarter of 2021. We ended the first quarter of 2021 with approximately $54.8 million in cash and cash equivalents, which we believe is sufficient to fund operations for at lea...